Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel

HIV 1-Infektionsanfälligkeit

Die Anfälligkeit gegenüber HIV1-Infektionen kann durch genetische Varianten im IL10-Gen, welches Interleukin 10 kodiert, vermittelt werden.

Gliederung

HIV-Resistenz
CCR5
CXCR1
HIV 1-Infektionsanfälligkeit
IL10

Referenzen:

1.

Rosenwasser LJ et. al. (1997) Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10).

[^]
2.

Shin HD et. al. (2000) Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10.

[^]
3.

Vasilescu A et. al. (2007) A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients.

[^]
4.

Burt TD et. al. (2008) Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression.

[^]
5.

Samson M et. al. (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

[^]
6.

Liu R et. al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

[^]
7.

Dean M et. al. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

[^]
8.

Smith MW et. al. (1997) Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.

[^]
9.

Winkler C et. al. (1998) Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC)

[^]
10.

Martin MP et. al. (1998) Genetic acceleration of AIDS progression by a promoter variant of CCR5.

[^]
11.

Carrington M et. al. (1999) HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.

[^]
12.

Liu H et. al. (1999) Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression.

[^]
13.

Migueles SA et. al. (2000) HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

[^]
14.

Faure S et. al. (2000) Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1.

[^]
15.

Gao X et. al. (2001) Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.

[^]
16.

An P et. al. (2002) Modulating influence on HIV/AIDS by interacting RANTES gene variants.

[^]
17.

Martin MP et. al. (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS.

[^]
18.

An P et al. (2003) A tumor necrosis factor-alpha-inducible promoter variant of interferon-gamma accelerates CD4+ T cell depletion in human immunodeficiency virus-1-infected individuals.

[^]
19.

Modi WS et. al. (2003) MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission.

[^]
20.

O'Brien SJ et. al. (2004) Human genes that limit AIDS.

[^]
21.

Nolan D et. al. (2004) Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground.

[^]
22.

None (2004) HIV-host interactions: vital to the virus and key to its inhibition.

[^]
23.

Lassen K et. al. (2004) The multifactorial nature of HIV-1 latency.

[^]
24.

Martin MP et. al. (2004) Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection.

[^]
25.

Kaslow RA et. al. (2005) Influence of host genetic variation on susceptibility to HIV type 1 infection.

[^]
26.

Gonzalez E et. al. (2005) The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.

[^]
27.

Colobran R et. al. (2005) Multiple products derived from two CCL4 loci: high incidence of a new polymorphism in HIV+ patients.

[^]
28.

Soriano A et. al. (2005) Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS.

[^]
29.

Gao X et. al. (2005) AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis.

[^]
30.

Granelli-Piperno A et. al. (2006) HIV-1 selectively infects a subset of nonmaturing BDCA1-positive dendritic cells in human blood.

[^]
31.

Schindler M et. al. (2006) Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1.

[^]
32.

Cressey TR et. al. (2007) Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.

[^]
33.

Jennes W et. al. (2006) Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands.

[^]
34.

Wilkin TJ et. al. (2007) HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

[^]
35.

Zhou T et. al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120.

[^]
36.

Hladik F et. al. (2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.

[^]
37.

Triboulet R et. al. (2007) Suppression of microRNA-silencing pathway by HIV-1 during virus replication.

[^]
38.

Gulick RM et. al. (2007) Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

[^]
39.

Jiménez-Baranda S et. al. (2007) Filamin-A regulates actin-dependent clustering of HIV receptors.

[^]
40.

Fellay J et. al. (2007) A whole-genome association study of major determinants for host control of HIV-1.

[^]
41.

Huang J et. al. (2007) Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes.

[^]
42.

Brass AL et. al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen.

[^]
43.

He W et. al. (2008) Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility.

[^]
44.

Mandl JN et. al. (2008) Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections.

[^]
45.

Kulkarni H et. al. (2009) The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry.

[^]
46.

Thomas R et. al. (2009) HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C.

[^]
47.

Manganaro L et. al. (2010) Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes.

[^]
48.

Kosmrlj A et. al. (2010) Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection.

[^]
49.

Cagliani R et. al. (2010) Genetic diversity at endoplasmic reticulum aminopeptidases is maintained by balancing selection and is associated with natural resistance to HIV-1 infection.

[^]
50.

Yan N et. al. (2010) The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1.

[^]
51.

Sironi M et. al. (2012) A common polymorphism in TLR3 confers natural resistance to HIV-1 infection.

[^]
52.

Zhang W et. al. (2011) T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction.

[^]
53.

Jäger S et. al. (2011) Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.

[^]
54.

Richardson MW et. al. (2012) Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection.

[^]
55.

Harman AN et. al. (2015) HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1.

[^]
56.

Yoh SM et. al. (2015) PQBP1 Is a Proximal Sensor of the cGAS-Dependent Innate Response to HIV-1.

[^]
57.

Sperandio S et. al. (2015) TOE1 is an inhibitor of HIV-1 replication with cell-penetrating capability.

[^]
58.

Usami Y et. al. (2015) SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef.

[^]
59.

Rosa A et. al. (2015) HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation.

[^]
60.

Ramsuran V et. al. (2018) Elevated expression impairs HIV control through inhibition of NKG2A-expressing cells.

[^]
Update: 8. Mai 2019